BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
Employees: 51-200
Phone: +1 510-521-3390
Founded date: 1990
Investors 1
| Date | Name | Website |
| - | Technology... | pivotcente... |
Mentions in press and media 7
| Date | Title | Description |
| 15.05.2015 | Stem cell genes are helping inform this startup’s approach to cancer diagnostics | OncoCyte actually draws its diagnostic capability from the kind of stem cell research going on at BioTime – because the company itself pivoted away from embryonic stem cell-based cancer therapeutics and into the diagnostics space. Several g... |
| 17.09.2014 | Abcodia to collaborate with OncoCyte Corporation on breast cancer diagnostic development | Abcodia to collaborate with OncoCyte Corporation on breast cancer diagnostic development 17-09-2014 OncoCyte Corporation, a subsidiary of BioTime, Inc. (NYSE MKT: BTX), and Abcodia Ltd., a UK-based company focusing on the early detection of... |
| 09.05.2014 | LifeMap Solutions Raises $5M Seed Funding | LifeMap Solutions, Inc., an Alameda, California-based medical technology startup focused on creating innovative mobile health (mHealth) products and services powered by big data, raised a $5m seed funding round. The round was led by parent ... |
| 09.05.2014 | The Xconomy SF Six: Funding for Udemy, Optimizely, & More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Here are the top six things we’re paying attention to in the San Francisco tech scene this week. –Yesterday, online teaching marketplace Udemy announced a $32 million Series C... |
| 28.01.2011 | Regenerative medicine startup Cell Targeting sold to BioTime | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| - | Stem cell genes are helping inform this startup’s approach to cancer diagnostics | A deep understanding of stem cell biology is helping Bay Area startup OncoCyte build out a new suite of cancer diagnostics. The company just raised $3.3 million from two private investors; it’s majority owned, however, by the publicly trade... |
| - | Regenerative medicine startup Cell Targeting sold to BioTime | Stem cell technology developer Cell Targeting has sold its assets to BioTime (AMEX:BTX) in a deal worth about $2.3 million. BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s common stock, which was trading around $7.7... |